Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 9:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 152 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetic Neuropathies, Painful Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nociceptive Pain Fiber Response

NCT02696070
View directory record Official record
Conditions
Painful Peripheral Diabetic Neuropathy
Interventions
Provant Therapy System
Device
Lead sponsor
Regenesis Biomedical, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time

NCT01223365
View directory record Official record
Conditions
Chronic Pain
Interventions
Hydrocodone ER
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
54
States / cities
Mobile, Alabama • Anaheim, California • Beverly Hills, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 3, 2026, 9:00 PM EDT
Completed No phase listed Observational

Observational Study of the the Use of a Trigeminal Vagal Nerve Stimulator in the Routine Care of Native Americans With Diabetic Neuropathy Pain. Pain Scores, Drug Use and Glucose Measurements Will be Assessed

NCT07025356
View directory record Official record
Conditions
Diabetic Neuropathy With Neurologic Complication
Interventions
Implantation of a trigeminal Vagus cervical nerve stimulator system, Implantation of a neurostimulator system for trigeminal vagal cervical nerve stimulation
Drug · Device
Lead sponsor
Vagus Nerve Society
Other
Eligibility
18 Years to 89 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pine Ridge, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)

NCT01474772
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Pregabalin, placebo
Drug · Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
34
States / cities
Goodyear, Arizona • Phoenix, Arizona • Fresno, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 1Phase 2 Interventional

Efficacy of Inhaled Cannabis in Diabetic Painful Peripheral Neuropathy

NCT00781001
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Cannabis
Drug
Lead sponsor
Center for Medicinal Cannabis Research
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 2 Interventional

IMX-150 Cream for Diabetic Neuropathy

NCT00641953
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
IMX-150, Placebo
Drug
Lead sponsor
Procris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Brooksville, Florida • Jupiter, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2008 · Synced Oct 3, 2026, 9:00 PM EDT
Recruiting Phase 2 Interventional

SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

NCT06614322
View directory record Official record
Conditions
Painful Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain (DPN), Chemotherapy Induced Peripheral Neuropathy (CIPN), Idiopathic Peripheral Neuropathy
Interventions
Pregabalin, Duloxetine, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 3, 2026, 9:00 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Peer Support for Patients With Diabetic Foot Ulcers

NCT06004219
View directory record Official record
Conditions
Diabetic Foot Ulcer, Diabetic Wound, Diabetes Mellitus, Type 2, Diabetic Foot, Diabetes Complications, Peripheral Neuropathy
Interventions
Peer counseling group
Behavioral
Lead sponsor
Casa Colina Hospital and Centers for Healthcare
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Downey, California • Los Angeles, California • Pomona, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 3, 2026, 9:00 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain

NCT01620775
View directory record Official record
Conditions
Chronic Low Back Pain, Diabetic Peripheral Neuropathy, Knee Osteoarthritis
Interventions
MRIs, Pain testing
Other
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

NCT01455415
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
55
States / cities
Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Results available

Study of DA-9801 to Treat Diabetic Neuropathy

NCT01822925
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
DA-9801 300mg, DA-9801 600mg, DA-9801 900mg, Placebo
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
Lakewood, California • Walnut Creek, California • Milford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 3, 2026, 9:00 PM EDT
Active, not recruiting Not applicable Interventional

Optimization of NIBS for Diabetic Neuropathy Neuropathic Pain

NCT03625752
View directory record Official record
Conditions
Diabetic Neuropathies, Chronic Pain
Interventions
Active Comparator: Active tDCS + Active TUS, Sham
Device
Lead sponsor
Case Western Reserve University
Other
Eligibility
40 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Not applicable Interventional Results available

The Effect of Natrox® Oxygen Wound Therapy on the Healing Rate of Chronic Diabetic Foot Ulcers

NCT03905863
View directory record Official record
Conditions
Diabetic Foot Ulcer, Surgical Wound
Interventions
Natrox® Oxygen Wound Therapy
Device
Lead sponsor
Inotec AMD Limited
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
19
States / cities
Los Angeles, California • Miami, Florida • Miami Lakes, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 4 Interventional

Training "Pain Connoisseurs" for Efficient Analgesic Proof-of-Concept Studies

NCT02842554
View directory record Official record
Conditions
Painful Diabetic Neuropathy (PDN)
Interventions
EPT, Drug Placebo Administration, C
Other · Drug
Lead sponsor
Analgesic Solutions
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy

NCT04469270
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
Engensis, Placebo
Biological · Other
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
16
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 3, 2026, 9:00 PM EDT
Terminated Phase 2 Interventional

A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.

NCT00625833
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
Placebo, [S,S]-Reboxetine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Anniston, Alabama • Birmingham, Alabama • Mission Viejo, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Results available

Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves

NCT01939366
View directory record Official record
Conditions
Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus
Interventions
Cebranopadol 100 µg, Cebranopadol 300 µg, Cebranopadol 600 µg, Pregabalin, Matching Placebo
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
Mesa, Arizona • Garden Grove, California • Laguna Hills, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 4 Interventional

Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain

NCT00266643
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
duloxetine hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Phoenix, Arizona • Fort Myers, Florida • Tallahassee, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2007 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Gene Therapy for Painful Diabetic Neuropathy

NCT01002235
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy
Interventions
VM202
Biological
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Walnut Creek, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Results available

A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)

NCT00643760
View directory record Official record
Conditions
Neuropathy, Diabetic
Interventions
Placebo, GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day, Pregabalin
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
90
States / cities
Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 3, 2026, 9:00 PM EDT
Terminated Phase 3 Interventional Results available

A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

NCT01063868
View directory record Official record
Conditions
Diabetic Neuropathy, Painful, Diabetic Polyneuropathy
Interventions
Tapentadol extended release (ER), Oxycodone controlled release (CR)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
23
States / cities
Mesa, Arizona • Tucson, Arizona • Fruitland Park, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 4 Interventional

Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy

NCT00903851
View directory record Official record
Conditions
Diabetes
Interventions
Lidoderm
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 90 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
4
States / cities
Birmingham, Alabama • Hueytown, Alabama • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2010 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 4 Interventional

Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

NCT00159679
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
30
States / cities
Hot Springs, Arkansas • La Jolla, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 3, 2026, 9:00 PM EDT
Not listed Phase 2 Interventional

A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy

NCT01537705
View directory record Official record
Conditions
Diabetic Neuropathy, Chemotherapy Induced Neuropathy, HIV Neuropathy, Trauma Induced Neuropathy
Interventions
Neuron012703 (Medical Food)
Drug
Lead sponsor
Targeted Medical Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2012 · Synced Oct 3, 2026, 9:00 PM EDT